TICKERNERD
Menu
NTLANTLAHealthcare · Biotechnology

NTLA Stock Forecast: Intellia Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$13
+7.60% on the day

The 20 Wall Street analysts covering Intellia Therapeutics, Inc. hold a median 12-month price target of $16 — +27.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 8 Oct 2026 — in the upper half.

Market cap
$1.7B
Ticker Nerd rank
53 / 100
Median analyst target
$16
Analysts covering
20
Revenue$7.7M−46.2% y/y
Operating income−$112.8M
Net income−$106.6M
Free cash flow−$84.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.0%
1M
−1.1%
YTD
+40.2%
1Y
−48.5%
From 52W high
−55.0%
From 52W low
+56.7%
$8
$28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NTLA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Intellia Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
53 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
93
Accruals
73
Issuance
58
Revisions
49
Momentum
47
Value
43
Quality
42
Size
37
Volatility
24

Growth (93): Sales and profits are climbing, and climbing faster than before.

Volatility (24): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NTLA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NTLA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26NTLAHigh $61Median $16Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says20 analysts
10 Buy6 Hold4 Sell
Low $8Median $16High $61

The green dot is the last close — the median target sits +27.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
9 Sept 2026CitizensReiteratesMarket Outperform$30
9 Sept 2026HC Wainwright & Co.ReiteratesBuy$25
9 Sept 2026WedbushMaintainsNeutral$12 → $13
25 Aug 2026CitizensReiteratesMarket Outperform—
25 Aug 2026CitizensReiteratesMarket Outperform$30
7 Aug 2026Evercore ISI GroupUpgradeOutperform—
7 Aug 2026Evercore ISI GroupUpgradeOutperform$16 → $24
16 July 2026Wolfe ResearchDowngradeUnderperform$9.00
16 July 2026Wolfe ResearchDowngradeUnderperform—
10 July 2026WedbushMaintainsNeutral$12 → $17
10 July 2026WedbushMaintainsNeutral—
16 June 2026Canaccord GenuityMaintainsBuy—
15 June 2026CitizensReiteratesMarket Outperform—
15 June 2026HC Wainwright & Co.ReiteratesBuy—
15 June 2026WedbushReiteratesNeutral—
13 May 2026BernsteinMaintainsMarket Perform—
13 May 2026HC Wainwright & Co.MaintainsBuy—
12 May 2026Canaccord GenuityMaintainsBuy—
12 May 2026WedbushReiteratesNeutral—
28 Apr 2026Canaccord GenuityMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NTLA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NTLA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Intellia Therapeutics, Inc. returned −48.5% against +16.2% for the S&P 500, dividends included.

NTLA vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26NTLAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NTLA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
8
Analysts cutting
7
Fundamentals

Intellia Therapeutics, Inc. (NTLA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.2×

Cheaper than 88% of US stocks

Price / sales
28.6×

Cheaper than 7% of US stocks

Price / book
2.3×

Cheaper than 39% of US stocks

EV / EBITDA
−3.3×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
−46.2%

Higher than 6% of US stocks

Earnings growth (YoY)
−46.2%

Higher than 11% of US stocks

Gross margin
—
Operating margin
−1472.3%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−55.4%

Higher than 20% of US stocks

Return on assets
−30.1%

Higher than 14% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Intellia Therapeutics, Inc. (NTLA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Intellia Therapeutics, Inc. has a market value of $1.7B and an enterprise value of $1.4B.

  • Revenue in the twelve months to 30 June 2026: $59.5M. The latest quarter shrank 46.2% year on year.

  • Net income over the same four quarters: −$400.0M, a −672.2% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.36.

  • Free cash flow in the twelve months to 30 June 2026: −$348.7M.

  • Shares outstanding: 140.0M.

  • Trailing P/E: −3.2×; forward P/E: −4.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Intellia Therapeutics, Inc. employs 377 people — $158K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

NTLA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NTLAIntellia Therapeutics, Inc.$1.7B
53
NUVBNuvation Bio, Inc.$1.7B
62
GENBGenerate Biomedicines, Inc.$1.8B
1
BHVNBiohaven Ltd.$1.7B
32
URGNUroGen Pharma Ltd.$1.8B
83
BRVEBraveheart Bio, Inc.$1.7B
0
ZYMEZymeworks, Inc.$1.8B
63

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Intellia Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NTLA news & analysis

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 2 Oct 2026neutral

Intellia Therapeutics announced that on October 1, 2026, it awarded inducement grants to eight new employees under its 2024 Inducement Plan, as amended, as a material inducement to employment. The grants were made under Nasdaq Listing Rule 5635(c)(4).

Why it matters — NTLA watchers would care because this shows the company is attracting and onboarding new talent through equity-based incentives, a routine corporate action notable for its implications on share dilution and hiring.

Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances

MarketBeat · 19 Sept 2026neutral

Intellia Therapeutics executives outlined plans for a potential launch of lonvo-z, its hereditary angioedema treatment, as the PDUFA date nears. They also discussed the ongoing Phase III program in transthyretin amyloidosis and the company's capital position during a Morgan Stanley event.

Why it matters — NTLA watchers would care because these updates provide insight into key pipeline milestones and financial readiness ahead of the lonvo-z regulatory decision.

Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?

Zacks Investment Research · 18 Sept 2026positive

NTLA received FDA priority review for its candidate lonvo-z, with a decision expected by March 10, 2027, which could lead to the company's first approved product. Meanwhile, nex-z studies are reported to be progressing well.

Why it matters — A priority review and the potential first product approval, along with steady progress in the nex-z program, signal pipeline advancement that NTLA watchers would track closely.

Intellia Therapeutics, Inc. (NTLA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 14 Sept 2026neutral

Intellia Therapeutics presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and the transcript of that presentation is now available. The event provided a forum for the company to discuss its business with the investment community.

Why it matters — A NTLA watcher would care because the appearance at a major healthcare conference offers a direct window into the company's current positioning and messaging to investors.

FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug

Zacks Investment Research · 9 Sept 2026positive

The FDA has accepted Intellia's Biologics License Application (BLA) for its hereditary angioedema (HAE) drug, lonvo-z, and granted it Priority Review. A regulatory decision is expected by March 10, 2027.

Why it matters — Priority Review signals faster regulatory evaluation of Intellia's HAE candidate, bringing the company closer to a potential approval decision.

FAQ

Frequently asked questions about NTLA stock

What is the NTLA stock price forecast for 2026-2027?

The 20 Wall Street analysts covering Intellia Therapeutics, Inc. have a median 12-month price target of $16, with estimates ranging from $8 to $61. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NTLA stock a buy right now?

Of the 20 analysts covering Intellia Therapeutics, Inc., 10 rate it a Buy, 6 a Hold and 4 a Sell. Ticker Nerd's systematic factor model ranks Intellia Therapeutics, Inc. 53 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NTLA?

As at 8 Oct 2026, Intellia Therapeutics, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (93 of 100).

Will NTLA stock go up?

No one can know that. What the data says: the median 12-month target from 20 analysts implies +27.0% from the last close, and Ticker Nerd's factor model ranks Intellia Therapeutics, Inc. 53 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NTLA stock forecast for 2030?

No analyst covering Intellia Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NTLA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $61 over the next 12 months.

How has NTLA stock performed over the past year?

Intellia Therapeutics, Inc. returned -48.5% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Intellia Therapeutics, Inc. do?

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing medicines built on CRISPR/Cas9 technology.

What is the latest news on NTLA?

The most recent item we track (GlobeNewsWire, 2 Oct 2026): "Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Intellia Therapeutics announced that on October 1, 2026, it awarded inducement grants to eight new employees under its 2024 Inducement Plan, as amended, as a material inducement to employment. The grants were made under Nasdaq Listing Rule 5635(c)(4).

Company

About Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing medicines built on CRISPR/Cas9 technology. Intellia Therapeutics develops both in vivo therapies, which edit genes inside the body, and ex vivo cell therapies, where cells are edited outside the body before being returned to the patient. Its current programs are centered on severe genetic and immune-related diseases, including rare disorders such as transthyretin amyloidosis and hereditary angioedema, as well as selected oncology and autoimmune applications. The company’s broader role in the market is to advance potentially curative treatment approaches that address the root cause of disease rather than symptoms. Intellia Therapeutics operates as a research-driven biopharmaceutical company, with a business model centered on clinical development, collaboration, and platform-based innovation in genetic medicine.

CEO Dr. John M. Leonard M.D. · 377 employees · United States · https://www.intelliatx.com